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Abstract
Hepcidin is the key regulator of iron homeostasis but data are limited regarding its temporal
response to iron therapy, and response to intravenous versus oral iron. In the 56-week,
open-label, multicenter, prospective, randomized FIND-CKD study, 626 anemic patients
with non-dialysis dependent chronic kidney disease (ND-CKD) and iron deficiency not
receiving an erythropoiesis stimulating agent were randomized (1:1:2) to intravenous ferric
carboxymaltose (FCM), targeting higher (400–600μg/L) or lower (100–200μg/L) ferritin, or
to oral iron. Serum hepcidin levels were measured centrally in a subset of 61 patients. Mean
(SD) baseline hepcidin level was 4.0(3.5), 7.3(6.4) and 6.5(5.6) ng/mL in the high ferritin
FCM (n = 17), low ferritin FCM (n = 16) and oral iron group (n = 28). The mean (SD) endpoint
value (i.e. the last post-baseline value) was 26.0(9.1),15.7(7.7) and 16.3(11.0) ng/mL,
respectively. The increase in hepcidin from baseline was significantly smaller with low ferri-
tin FCM or oral iron vs high ferritin FCM at all time points up to week 52. Significant correla-
tions were found between absolute hepcidin and ferritin values (r = 0.65, p<0.001) and
between final post-baseline increases in both parameters (r = 0.70, p<0.001). The increase
in hepcidin levels over the 12-month study generally mirrored the cumulative iron dose in
each group. Hepcidin and transferrin saturation (TSAT) absolute values showed no correla-
tion, although there was an association between final post-baseline increases (r = 0.42,
p<0.001). Absolute values (r = 0.36, p = 0.004) and final post-baseline increases of hepcidin
and hemoglobin (p = 0.30, p = 0.030) correlated weakly. Baseline hepcidin levels were not
predictive of a hematopoietic response to iron therapy. In conclusion, hepcidin levels rose in
response to either intravenous or oral iron therapy, but the speed and extent of the rise was
greatest with intravenous iron targeting a higher ferritin level. However neither the baseline
level nor the change in hepcidin was able to predict response to therapy in this cohort.
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Introduction
Since its discovery in 2001 [1, 2], the peptide hormone hepcidin has been identified as the prin-
cipal regulator of iron availability in the body. It maintains iron homeostasis by controlling
intestinal absorption of dietary iron and release of iron from the liver and spleen [3]. Hepcidin
acts by binding to, and inducing internalization of, the transmembrane iron transporter pro-
tein ferroportin, thus blocking export of iron from enterocytes, macrophages and parenchymal
hepatocytes into the circulation. When iron availability is inadequate, low hepcidin levels
promote enhanced intestinal iron uptake and release of stored iron. Hepcidin levels rise in
response to iron repletion such that iron absorption and release are reduced. Stimulation of
erythropoiesis, conversely, lowers hepcidin levels through increased production of erythrofer-
rone by erythroblasts [4]. Furthermore, hepcidin levels are increased in the presence of chronic
inflammation, such as in patients with chronic kidney disease (CKD) [5–8], contributing to the
functional iron deficiency which is frequently observed in this patient population.
The key regulatory role of hepcidin has prompted interest in the possibility that it may rep-
resent a more reliable indicator of iron status than current biomarkers such as ferritin [3, 9, 10]
and indeed may represent a useful therapeutic target [11]. As with ferritin, however, the predic-
tive value of hepcidin is complicated by the influence of inflammation on hepcidin levels [3,
12], and by high intra-individual variation [13]. Data are conflicting regarding an association
between hepcidin and the erythropoietic response to erythropoiesis stimulating agent (ESA)
therapy [13–17], or iron therapy [13, 16, 18–22]. The longitudinal response of hepcidin levels
to iron therapy has not been examined, nor are there any data comparing the short- or long-
term hepcidin response to intravenous (IV) versus oral iron therapy. Additionally, the associa-
tions between hepcidin and other markers of iron status, or anemia, are poorly defined.
The Ferinject1 assessment in patients with Iron deficiency anemia and Non-Dialysis
dependent Chronic Kidney Disease (FIND-CKD) study was a randomized, international, trial
of IV ferric carboxymaltose (FCM) versus oral iron in patients with non-dialysis dependent
CKD, anemia, and iron deficiency not receiving ESA therapy [23]. As part of the study proto-
col, hepcidin levels were measured in a subset of patients throughout the 12-month study. The
current exploratory analysis was undertaken post hoc with the objective of determining the
response of hepcidin levels to IV or oral iron treatment over time.
Methods
Study design
FIND-CKD was a 56-week, open-label, multicenter, prospective, randomized, three-arm study
undertaken at 193 nephrology centers in 20 countries (ClinicalTrials.gov NCT00994318). The
first patient visit took place in December 2009, with the final patient visit in January 2012. The
study design has been described in full elsewhere [24] and is summarized here. The study pro-
tocol was approved at all participating sites (see S1 Appendix for a list of Ethics Committees).
The study was conducted according to the principles of the Declaration of Helsinki and the
ICH Guidelines for Good Clinical Practice. All patients provided written informed consent.
The primary endpoint of the study was time to initiation of other anemia management,
specified as ESAs, blood transfusion, use of an alternative iron therapy, or occurrence of a
Hb trigger (two consecutive Hb values<10 g/dL on or after week 8). Pre-planned analyses
included the correlations between hepcidin and iron parameters (ferritin and transferrin satu-
ration [TSAT]) at baseline and by visit, both for absolute values and for change from baseline.
Other analyses reported here were performed post hoc.
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Study population
Full eligibility criteria have been published previously [24]. In brief, adult (18 years) patients
with non-dialysis dependent CKD were enrolled if (a) at least one Hb level was 9–11 g/dL
within four weeks of randomization, (b) any ferritin level was<100 μg/L, or<200 μg/L with
TSAT<20%, within four weeks of randomization, (c) estimated glomerular filtration rate
(eGFR) was60 mL/min/1.73m2 (d) no ESA had been administered within four months of
randomization, (e) no documented history of gastrointestinal intolerability to oral iron (e) no
known active infection and baseline C-reactive protein (CRP) 20 mg/L.
Study treatment
Patients were randomized in 1:1:2 ratio to high ferritin FCM: low ferritin FCM: oral iron. FCM
dose (Ferinject1, Vifor International, St Gallen, Switzerland) in the high ferritin and low
ferritin FCM groups was adjusted to target a ferritin level of 400–600 μg/L and 100–200 μg/L,
respectively. An initial single dose was administered on day 0: 1000 mg iron as FCM in the
high ferritin FCM group (500 mg iron on days 0 and 7 in patients weighing66 kg) and 200
mg iron as FCM in the low ferritin FCM group if ferritin was<100 μg/L. During weeks 4 to 48,
FCM was administered every four weeks in the high ferritin FCM group at a dose of 500 mg
iron if ferritin was in the range 200 to<400 μg/L, and at a dose of 1000 mg iron if ferritin was
<200 μg/L, and in the low ferritin FCM group at a dose of 200 mg iron if ferritin was<100 μg/
L. In both groups, dosing was withheld if TSAT was40%. Oral iron therapy consisted of com-
mercially-available ferrous sulfate at a dose of 304 mg (100 mg of iron) twice daily.
Until week 8 post-randomization, patients were not to receive ESAs, blood transfusion or
any anemia therapy other than study drug unless there was an absolute requirement.
Hepcidin
All UK patients had hepcidin levels in serum samples measured at baseline (week 0) and at
weeks 4, 8, 12, 24, 36 and 52 post-randomization. Hepcidin was measured at King’s College
London in serum using ultra-high pressure liquid chromatography (UPLC) and a triple-qua-
druple mass spectrometer based on published methodology [25]. Due to a change of mass spec-
trometer, the assay has undergone a further validation [26]. The lower limit of quantitation
was 0.1 ng/mL with less than 20% precision and accuracy.
Statistical analysis
All patients who received at least one dose of randomized treatment (or according to the proto-
col were not treated due to ferritin level) and who attended at least one post-baseline visit were
included in the intention-to-treat (ITT) population. Hepcidin data were analyzed for all ITT
patients with a baseline hepcidin value and at least one post-baseline value (i.e. the 'hepcidin
subpopulation'). The statistical analysis plan specified that hepcidin values were included only
up to the point at which the primary endpoint was met (i.e. another anemia therapy was initi-
ated) or the end of the study (for patients who did not meet primary endpoint).
All analyses were based on the natural scale (i.e. untransformed data). Summary statistics
are provided for baseline and post-baseline hepcidin levels by treatment group. The change in
hepcidin level from baseline to each post-baseline time point was compared within each treat-
ment group using the Student paired t-test. The pairwise comparisons of treatment groups in
the change in hepcidin values from baseline to all post-baseline visits were assessed by a mixed
model with repeated measures procedure, using treatment group, baseline hepcidin value,
visit, age at baseline and interaction between visit and treatment as covariates. The correlation
Hepcidin Response to Iron Therapy: FIND-CKD Trial
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between observed hepcidin levels versus ferritin, TSAT, Hb and estimated GFR (GFR) levels,
and between changes in levels from baseline, was assessed by Pearson coefficients across
patients in all treatment groups, using endpoint values (i.e. the last non-missing post-baseline
value recorded). Correlations were analyzed similarly within each treatment group at weeks 8
and 24. Patient numbers were considered too low after week 24 for within-group analyses,
although positive correlations in either FCM treatment arm prompted an additional assess-
ment at week 52 or endpoint, and/or in pooled FCM groups. All assessments of correlations
between hepcidin and ferritin, TSAT, Hb and eGFR included only values recorded on the same
sample date. Ferritin and Hb values measurements were based on central analysis; TSAT values
were obtained locally. eGFR based on locally-measured serum creatinine values was calculated
based on the Modification of Diet in Renal Disease-4 (MDRD-4) equation.
As an exploratory analysis, the hazard ratios and associated 95% confidence intervals for the
primary endpoint of the study (time to initiation of other anemia management or occurrence of
hepcidin trigger [24]) were calculated using Cox proportional hazards modeling adjusting for
(a) hepcidin at baseline (b) change in hepcidin to week 8 and (c) change in hepcidin to week 24.
All statistical analyses were performed using SAS Version 9.3 (SAS Institute Inc. SAS/STAT,
Cary, NC, USA).
Results
Study population
In total, 613 patients formed the ITT population, of whom 71 patients were recruited in the
UK and were candidates for the hepcidin substudy. Of these, 61 provided both a baseline and
1 post-baseline value and formed the hepcidin subpopulation (17 high ferritin FCM, 16 low
ferritin FCM, 28 oral iron). During the 12-month study, a total of 10 patients received an alter-
native anemia therapy at some point (2 high ferritin FCM, 2 low ferritin FCM, 6 oral iron), and
in these patients subsequent hepcidin values were excluded from analysis since this could have
affected hepcidin concentrations. Overall, hepcidin data were available from 59, 56, 57, 48, 41
and 28 patients at weeks 4, 8, 12, 24, 36 and 52, respectively (Fig 1) (S1 Table).
The characteristics of the patients included in the hepcidin subpopulation (Table 1) showed
no relevant differences to the rest of the study population [21].
Hepcidin levels over time
Mean (SD) hepcidin level at baseline was 4.0 (3.5), 7.3 (6.4) and 6.5 (5.6) ng/mL in the high fer-
ritin FCM, low ferritin FCM and oral iron groups, respectively. These values were broadly simi-
lar to the normal range for healthy individuals of this age group based on the assay used in this
analysis [25].
Post-baseline, the highest hepcidin values were observed in the high ferritin FCM group at all
time points (Fig 2a). The change from baseline was statistically significant at all post-baseline
visits in the high ferritin FCM group and the low ferritin group while for the oral iron group the
change was significant except for week 8 (p = 0.063) (Fig 2a). The mean (SD) endpoint value
(i.e. the last non-missing value recorded after baseline) was 26.0 (9.1), 15.7 (7.7) and 16.3 (11.0)
ng/mL in the high ferritin FCM, low ferritin FCM and oral iron groups, respectively.
The increase in hepcidin was significantly smaller in the low ferritin FCM group and the
oral iron group compared to the high ferritin FCM group at all post-baseline time points other
than week 52 (Fig 2b). Other predictive factors for the increase in hepcidin were baseline hepci-
din (p = 0.038) and time from start of treatment (i.e. study visit) (p<0.001). The post-baseline
hepcidin increase was similar in the low ferritin FCM group and the oral iron group at all times
(Fig 2b).
Hepcidin Response to Iron Therapy: FIND-CKD Trial
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Hepcidin level and iron dose
The change in hepcidin level over the 12-month study generally mirrored the cumulative iron
dose administered in each of the three treatment groups (Fig 3). However, most FCM in the
Fig 1. Patient disposition (hepcidin subpopulation). Disposition according to treatment group is shown in S1 Table.
doi:10.1371/journal.pone.0157063.g001
Table 1. Patient demographics and baseline characteristics.
Hepcidin subpopulationa (n = 61) Patients not included in hepcidin analysis (n = 552)
Age,years Mean (SD) 66.1 (13.8) 69.4 (13.1)
Female gender n (%) 35 (57.4) 346 (62.7)
White race n (%) 46 (75.4) 538 (97.8)
Hb, g/dL Mean (SD) 10.4 (0.8) 10.4 (10.7)
Ferritin, μg/L Mean (SD) 55 (35) 57 (47)
TSAT, %b Mean (SD) 18 (7) 16 (11)
CRP, mg/Lb Mean (SD) 6.7 (5.6) 5.7 (8.7)
a Deﬁned as all ITT patients with a baseline hepcidin value and at least one post-baseline value
b Local laboratory
Hb, hemoglobin; CRP, C-reactive protein; SD, standard deviation; TSAT, transferrin saturation.
doi:10.1371/journal.pone.0157063.t001
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Fig 2. (a) Observed mean (SD) hepcidin level at each visit by treatment group. The p values indicate change from
baseline (student paired t test). (b) Least square [LS] mean change in hepcidin level from baseline to each visit by
treatment group by a mixed model with repeated measures procedure, with treatment group and baseline hepcidin as
covariates. The p values refer to the comparison of change from baseline in the low ferritin FCM group or oral group
versus the high ferritin FCM group. All differences between the low ferritin FCM and oral iron groups for the mean change
in hepcidin level from baseline were non-significant (p>0.05). In both graphs, only values obtained prior to the start of
alternative anemia therapy are included.
doi:10.1371/journal.pone.0157063.g002
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Fig 3. Mean hepcidin level andmean iron dose administered at each visit for (a) high ferritin FCM (b)
low ferritin FCM (c) oral iron. Bars indicate iron dose per visit and cumulative iron dose, lines indicate mean
hepcidin level. Only values obtained prior to the start of alternative anemia therapy are included BL, baseline;
FCM, ferric carboxymaltose.
doi:10.1371/journal.pone.0157063.g003
Hepcidin Response to Iron Therapy: FIND-CKD Trial
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high ferritin group was administered at the early study visits (S1 Fig), as was a high proportion
of FCM in the low ferritin group, whereas daily oral dosing was continued throughout the
study (Fig 3). The mean hepcidin level increased rapidly and remained elevated after the first
high ferritin FCM dose (Fig 3a), with a similar but less profound pattern of change in the low
FCM group (Fig 3b). Hepcidin levels increased more slowly and progressively over the
52-week study in response to oral iron therapy (Fig 3c).
Association between hepcidin level and markers for iron status
Serum ferritin. In the total hepcidin substudy population, there was a significant correla-
tion between hepcidin and ferritin levels at baseline (r = 0.43, p<0.001) and at the study end-
point (i.e. the last available post-baseline visit values) (r = 0.65, p<0.001) (Fig 4a). At higher
ferritin levels the association between hepcidin and ferritin seems to plateau although the
patient numbers at these high levels are too low to draw firm conclusions. There was also a
close correlation between change in hepcidin and change in ferritin from baseline to the end-
point value (r = 0.70, p<0.001) (Table 2). Fig 5 shows the correlation between hepcidin and fer-
ritin levels in the high ferritin FCM group at baseline, week 8 and week 24, illustrating that the
correlation was similar at low or high ferritin levels (i.e. before or after the start of high ferritin
FCM administration).
TSAT. Hepcidin did not correlate with TSAT at baseline in the overall hepcidin study
population (r = -0.01, p = 0.91). Neither was any significant correlation observed for absolute
hepcidin and TSAT based on endpoint values (r = 0.12, p = 0.34) (Fig 4b). The change in hepci-
din versus the change in TSAT from baseline to the endpoint value, however, was significant
(r = 0.42, p<0.001) but the correlation was less strong than for serum ferritin (Table 2). The
correlations between hepcidin and TSAT remained significant based on endpoint values for
the pooled FCM cohort, both for absolute values (r = 0.59, p<0.001; n = 33) and change from
baseline (r = 0.69, p<0.001; n = 33).
Association between hepcidin level and Hb. At baseline, there was no association
between absolute values for hepcidin and Hb values across all patients (r = 0.02, p = 0.88).
There was a relatively weak, albeit significant, positive correlation for endpoint values (r = 0.36,
p = 0.004) (Fig 4c) and between the change in hepcidin and change in Hb from baseline to the
endpoint value (r = 0.30, p = 0.030) (Table 2).
Hepcidin as a predictor of response to iron therapy. Baseline hepcidin values and the
mean hepcidin increase from baseline to week 8 and week 24 were calculated within each treat-
ment group for the subsets of patients with or without an increase in Hb of>1g/dL,>0.5g/dL
or 0 g/dL at the same time point. No association was observed between baseline hepcidin or
hepcidin increase and the Hb increase in either FCM treatment group using any of the cut-off
points. In the oral iron group, mean baseline hepcidin was lower in patients who achieved an
increase in Hb of>1 g/dL versus patients who did not at week 8 (mean 0.1 ng/mL [n = 1] ver-
sus 7.4 ng/mL [n = 20]) and at week 24 (mean 4.9 ng/mL [n = 6] versus 7.4 ng/mL [n = 11]),
but patient numbers were low.
Multivariate exploratory analysis showed no association between the primary endpoint of
the study (time to initiation of other anemia management or occurrence of Hb trigger) with
hepcidin level at baseline (HR 0.92; 95% CI 0.73, 1.16; p = 0.49), the change in hepcidin from
baseline to week 8 (HR 0.96; 95% CI 0.83, 1.11; p = 0.56) or the change to week 24 (HR 1.22;
95% CI 0.88, 1.68; p = 0.24) as covariates.
Association between hepcidin level and eGFR. There was no association between eGFR
and hepcidin values at baseline (r = 0.22, p = 0.085), week 8 (r = 0.16, p = 0.24) or week 24
(r = 0.08, p = 0.61).
Hepcidin Response to Iron Therapy: FIND-CKD Trial
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Fig 4. Correlation between hepcidin levels and (a) ferritin level (b) TSAT level (c) Hb level at study
endpoint for the hepcidin substudy population.Only values with the same sample date, and obtained
prior to the start of alternative anemia therapy, are included. Solid lines indicate the quadratic regression line.
Shaded areas indicate 95% CI of the regression line.
doi:10.1371/journal.pone.0157063.g004
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Discussion
These are the first results from a prospective, randomized trial using defined iron therapy regi-
mens to examine the three-way relationship between iron therapy, ferritin and hepcidin in
patients with non-dialysis dependent CKD. Data over a one-year period show that hepcidin
levels rise in response to iron therapy regardless of when the iron is administered periodically
via IV administration or continuously via daily oral dosing. However, the speed and extent of
the rise was greatest with IV iron targeting a higher ferritin level than with oral iron or when
Table 2. Correlations between change in hepcidin levels from baseline versus change in serum ferri-
tin, TSAT and Hb levels from baseline. Significant p values are shown in bold.
Correlation with change in hepcidin from baseline
n R P value
Change in serum ferritin from baseline, ng/mL
Endpoint values All patients 61 0.70 <0.001
Week 8
High ferritin FCM 16 0.29 0.28
Low ferritin FCM 16 0.72 0.001
Oral iron 24 -0.34 0.11
Week 24
High ferritin FCM 15 0.70 0.004
Low ferritin FCM 14 -0.04 0.88
Oral iron 19 0.23 0.33
Change in TSAT from baseline, %
Endpoint values All patients 61 0.42 <0.001
Week 8
High ferritin FCM 16 0.45 0.077
Low ferritin FCM 16 0.05 0.86
Oral iron 24 0.38 0.068
Week 24
High ferritin FCM 15 0.67 0.006
Low ferritin FCM 14 0.30 0.30
Oral iron 18 0.03 0.92
Change in Hb from baseline, g/dL
Endpoint values All patients 54 0.30 0.030
Week 8
High ferritin FCM 9 0.09 0.81
Low ferritin FCM 15 -0.28 0.31
Oral iron 20 0.16 0.49
Week 24
High ferritin FCM 13 0.53 0.064
Low ferritin FCM 13 -0.11 0.71
Oral iron 15 -0.27 0.33
Correlation estimates and p values were from the Pearson statistics (r)
Endpoint values represent the last non-missing post-baseline value recorded
All assessments included only values recorded on the same sample date. Only data prior to start of
alternative anemia therapy are included.
FCM, ferric carboxymaltose; TSAT, transferrin saturation.
doi:10.1371/journal.pone.0157063.t002
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IV iron was used to target a lower ferritin level, reflecting differences in the rate of delivery of
iron with each type of treatment.
Baseline hepcidin levels were within, or close to, the upper threshold for healthy controls in
this population of non-dialysis dependent patients with CKD. This reflects the fact that this
was an iron-deficient, relatively healthy cohort in which low levels of CRP indicated minimal
chronic inflammation. At all time points there was a clear and significant correlation between
serum hepcidin level and ferritin level. This is consistent with published data in hemodialysis
patients [5, 6, 15, 18, 19, 27] and, as in our population, non-dialysis dependent patients with
CKD [5, 20]. The utility of hepcidin as a marker for iron stores is limited, however, due to the
high intra-individual variation in hepcidin levels [13]. An important regulator of hepcidin is
inflammation, which stimulates production of hepcidin [3, 12], and chronic inflammation
becomes most prominent as renal function declines [28]. Hepcidin levels correlate with the
inflammatory marker C-reactive protein in patients on dialysis [13, 29, 30] or in non-dialysis
dependent CKD [7, 20], and the wide intra-patient variability in hepcidin levels may reflect
short-term fluctuations in the inflammatory state [13]. Thus, hepcidin levels may not be a reli-
able guide to whether iron therapy is required for patients with chronic inflammation, a situa-
tion which is already known to apply when ferritin is used as a biomarker for iron status.
In the complete cohort the correlation between hepcidin and TSAT levels was not signifi-
cant, although the change from baseline to endpoint in both values did attain significance.
However the window between iron administration and sampling may have influenced this
result [21] since in the oral iron group, iron was administered daily whereas in the IV iron
group iron was administered at least 4 weeks prior to blood sampling. Other authors have
observed a significant positive association between hepcidin and TSAT in peritoneal dialysis
Fig 5. Correlation between hepcidin levels and ferritin level at baseline, week 8 and week 24 for patients in the high ferritin FCM
group (n = 17).Only values with the same sample date, and obtained prior to the start of alternative anemia therapy, are included
Correlation between hepcidin levels and (a) ferritin level (b) TSAT level (c) Hb level at study endpoint for the hepcidin substudy population.
Only values with the same sample date, and obtained prior to the start of alternative anemia therapy, are included. Solid lines indicate the
quadratic regression line. Shaded areas indicate 95% CI of the regression line. Correlation between hepcidin levels and (a) ferritin level (b)
TSAT level (c) Hb level at study endpoint for the hepcidin substudy population. Only values with the same sample date, and obtained prior
to the start of alternative anemia therapy, are included. Solid lines indicate the quadratic regression line. Shaded areas indicate 95% CI of
the regression line.
doi:10.1371/journal.pone.0157063.g005
Hepcidin Response to Iron Therapy: FIND-CKD Trial
PLOS ONE | DOI:10.1371/journal.pone.0157063 June 8, 2016 11 / 15
[27] and non-dialysis dependent patients with CKD [20], but Ford et al, in their assessment of
28 hemodialysis patients, also found no significant correlation [13].
Neither baseline hepcidin levels nor change in hepcidin levels predicted the response to iron
therapy whereas a very weak association between endpoint hepcidin levels and hemoglobin lev-
els was found. Theoretically low baseline levels of hepcidin are associated with reduced sys-
temic iron levels and increased capacity to absorb oral iron, and thus identify successful
candidates for oral iron therapy. The effect of a marked increase in hepcidin on treatment
response is harder to anticipate. If hepcidin is a marker of iron load and concurs with increased
iron stores, increased levels are associated with successful therapy. However, if increased levels
of hepcidin designate reduced absorption and reduced iron release from the iron stores a
marked increase in hepcidin would be associated with resistance to therapy. In this study we
observed no evidence that the latter contention is true. Overexpression of ferroportin in
response to high iron levels may permit export of iron from macrophages into the circulation
even when hepcidin levels are elevated [31]. In our analysis, there was no significant association
between change in hepcidin levels and achievement of Hb thresholds or the primary endpoint
of the study. Reports in the literature regarding a role for hepcidin in predicting response to
therapy are relatively limited [10, 13, 16–20]. A single-arm study in 51 patients on hemodialysis
with iron deficiency examined the association between hepcidin levels and response to oral
iron therapy [18]. All patients had been receiving an ESA but no iron therapy for the three
month prior to study entry, at which point oral ferrous fumarate 50 mg/ day was given for
eight weeks. In the 16 patients who were Hb responders (i.e. Hb increase of 2 g/dL or higher),
mean hepcidin was significantly lower than in non-responders (10.8 versus 32.8 ng/mL,
p<0.05) [18]. Chand et al studied 129 patients with non-dialysis CKD given IV iron therapy,
and on multivariable analysis observed hepcidin to be significantly predictive of Hb increase by
week 8 after the start of iron infusion (p = 0.002) [20]. In contrast, Tessitore et al found baseline
hepcidin levels to show no significant association with the response to IV iron [19]. In their
series of 56 hemodialysis patients, multivariate analysis indicated that serum hepcidin level was
not a significant predictor for an increase in Hb following IV iron therapy in addition to main-
tenance ESA therapy [19].
Research into the role of serum hepcidin as a biomarker has been hampered by accurate,
consistent concentration measurements [32]. Different assay methods and a lack of standardi-
zation have made between-study comparisons difficult [33]. Absolute values for hepcidin in
urine or plasma samples can vary by up to 10-fold between assay types and centers [34, 35].
Here, we used a validated liquid chromatography tandem mass spectrometry assay. This is
more robust than immunoassays for detecting hepcidin (such as ELISA) which have been used
in other investigative studies of hepcidin as a biomarker, and which cross-react with other hep-
cidin isoforms such as hepcidin-22 and hepcidin-20. The study also benefitted from its pro-
spective, randomized design, and the extended 12-month longitudinal recording of hepcidin
values. The population size was limited by the fact that only patients recruited in the UK took
part in the substudy, but this ensured consistent measurement of hepcidin at a single center
using a single assay. It should be noted that hepcidin values were excluded if patients reached
the primary endpoint—which included initiation of ESA therapy—so these findings do not
necessarily apply to CKD patients receiving ESAs. Similarly, baseline hepcidin values were low,
indicating that the patient population did not have chronic inflammation (the study protocol
excluded patients with active infection or baseline CRP 20 mg/L), limiting extrapolation to
more inflamed patient groups. Lastly, we recognise that over the course of this one-year study
hepcidin data were available in a declining number of patients, with fewer than half the hepci-
din population providing values at one year. This effect was exacerbated by exclusion of
patients in whom alternative anemia management was started. This avoided contamination of
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data regarding the relative effect of the randomized therapies, and effectively provided a 'per
protocol analysis', but it also substantially reduced the data set over time.
This is the first analysis to prospectively assess the response of hepcidin levels to different
iron treatments. Results from these pre-specified and post hoc analyses showed that baseline
hepcidin levels were in the normal range, consistent with the presence of iron deficiency, ane-
mia and low inflammatory state. With either IV or oral iron therapy, the increase in hepcidin
correlated with the administered dose of iron. Changes in hepcidin levels showed a close corre-
lation with the level of stored iron, as measured by ferritin, but not either TSAT or Hb levels.
Hepcidin levels were not predictive for hematopoietic response to iron therapy in this popula-
tion, although the size of this population and the increasing proportion of non-evaluable
patients as the study progressed precludes firm conclusions. Further prospective studies, specif-
ically in patients with chronic inflammation, are awaited.
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